Can You Breastfeed With Ulcerative Colitis?

Yes, you can almost always breastfeed with ulcerative colitis. In August 2025 a global consensus of 39 IBD and content experts and 7 patient advocates, published simultaneously in six journals, recommended breastfeeding for women with IBD and stated that it is not associated with a higher risk of flares (Mahadevan 2025). The same consensus says mothers taking 5-ASAs, sulfasalazine, steroids, thiopurines and every current biologic may breastfeed. The two exceptions are the newer tablets: JAK inhibitors and S1P receptor modulators.

That one paragraph is the answer most pages stop at. It is not the end of the question for most people asking it, because the practical problems sit underneath: whether "detected in breast milk" means your baby is exposed, why your GI and your paediatrician may give you different answers about live vaccines, whether you need to pump and dump after a colonoscopy, whether breastfeeding will make you flare, and whether it will protect your child from getting UC. Those are the questions the r/UlcerativeColitis threads keep asking, and they are what this article is built around.

A note on what we read. We could not obtain the full text of the 2025 consensus, which sits behind publisher paywalls. We read its abstract and its full list of recommendations as published on Guideline Central with the American College of Gastroenterology. Where we quote it below, we are quoting that statement list, not the discussion behind each statement. Everything else here comes from studies and drug-safety records we opened, and where they disagree we say so.

What the 2025 global consensus actually says about breastfeeding

The consensus has a section headed "Medications during lactation", and it is short enough to give in full. Here are its statements as published in the recommendation list (Mahadevan 2025):

• "We recommend breastfeeding as it is not associated with an increased risk of disease exacerbation in women with IBD." Graded as a strong recommendation, very low certainty evidence.
• "We suggest counseling that infants born to mothers on anti-TNF therapy who breastfeed have no increased risk of infection in the first 12 months of life." A conditional recommendation, very low certainty.
• Mothers currently on 5-ASA or sulfasalazine may breastfeed.
• Mothers currently on thiopurines may breastfeed.
• Mothers currently on corticosteroids may breastfeed.
• Mothers currently on anti-TNF agents (infliximab, adalimumab, golimumab, certolizumab) may breastfeed.
• Mothers currently on anti-integrins (vedolizumab, natalizumab) may breastfeed.
• Mothers currently on anti-IL-12/23 and anti-IL-23 agents (ustekinumab, risankizumab, mirikizumab, guselkumab) may breastfeed.
• Mothers currently on biosimilars may breastfeed.
• Mothers currently on S1P receptor modulators (etrasimod or ozanimod) should not breastfeed.
• Mothers currently on JAK inhibitors (tofacitinib, upadacitinib, filgotinib) should not breastfeed.

Two things about that list are worth understanding before you lean on it.

"Strong recommendation, very low certainty" is not a contradiction. It means the panel is confident about what most women in your position would want once they understand the trade-off, even though the evidence base is a handful of small observational studies. There is no randomised trial of breastfeeding in IBD, and there never will be. The recommendation rests on the absence of any signal of harm plus everything else known about breastfeeding, not on proof.

The IL-23 statements are based on physiology, not trials. The press release that accompanied the consensus said so plainly: the recommendation to breastfeed on all monoclonal antibodies, including the newer IL-23 drugs, was made "even though there is not yet clinical trial data", based on how antibodies move into milk (UCSF via Newswise, 2025). That is a reasonable inference, and it is also an honest gap. If you are on risankizumab, mirikizumab or guselkumab, the evidence specific to your drug is thinner than for infliximab or vedolizumab.

The consensus was funded by the Helmsley Charitable Trust, according to the press release, not by a drug company. We did not read the individual authors' conflict-of-interest statements, so we cannot tell you whether any of them consult for the makers of the drugs discussed.

Why this matters more than it should

You might expect every gastroenterologist to know this already. A 2025 international survey of 856 gastroenterologists from 36 countries suggests otherwise (Casanova 2025). Thirteen percent believed that all IBD drugs were safe during breastfeeding. Only 59% advised against tofacitinib, 57% against upadacitinib and 54% against ozanimod while breastfeeding, which means a large minority would not have warned a nursing mother off the two drug classes the consensus now says to avoid. At the other end, 9% advised against thiopurines and 6% against ustekinumab, both of which the consensus now says are compatible.

So it is entirely possible to get advice in clinic that differs from the consensus, in either direction. That is not a reason to distrust your doctor. It is a reason to ask which source the advice comes from, and to bring the consensus statement list with you if the answer surprises you.

Does breastfeeding make ulcerative colitis flare?

No study has shown that breastfeeding itself causes UC to flare. The worry comes from an older study that did find a link at first glance, and the reason it found one is the most useful thing in this article for anyone weighing up whether to breastfeed.

In 2005, Kane and Lemieux reviewed 122 women with IBD who had given birth in the previous five years at a US tertiary centre (Kane 2005). Only 44% had breastfed. Of the 54 who did, 23 (43%) had a postpartum flare. Unadjusted, breastfeeding looked like it more than doubled the odds of a flare (odds ratio 2.2). But look at what happened next:

• Split by condition, the association lived entirely in Crohn's disease (odds ratio 3.8). For ulcerative colitis, the odds ratio was 0.89, with a confidence interval of 0.29 to 2.7. No association.
• Adjusted for stopping medication, the overall association became non-significant. The authors concluded that any relationship "may be more a consequence of discontinuation of IBD therapies."
• Among the reasons women gave for not breastfeeding were a physician's recommendation and fear of medication interactions.

In other words, many women stopped their treatment so they could breastfeed, then flared, and the flare was blamed on breastfeeding.

A Canadian population-based study published four years later found no increase either (Moffatt 2009). Using the University of Manitoba IBD Research Registry, it compared postpartum-year flare rates in women who did and did not breastfeed. For UC, 29.2% of those who breastfed flared, against 44.4% of those who did not (odds ratio 0.51, 95% confidence interval 0.12 to 2.2). That looks like a protective effect, and the authors suggested breastfeeding "may even provide a protective effect". With only 39 women with UC in the analysis and a confidence interval running from a large benefit to a doubling of risk, the honest reading is "no evidence of harm", not "breastfeeding prevents flares".

The real postpartum risk

The months after birth are a genuine risk window for UC, for reasons that have nothing to do with feeding. In a US study of 206 women with IBD, about a third flared within the year after delivery, and the strongest predictors were disease activity in the third trimester and cutting back treatment either during pregnancy (odds ratio 3.00) or after it (odds ratio 4.43) (Yu 2020). Our article on UC flares during pregnancy covers that postpartum window in detail, including blood-clot risk, so we will not repeat it here.

The point that matters for breastfeeding is the overlap. If the decision to breastfeed leads someone to stop or reduce a treatment that was keeping UC quiet, the de-escalation is what the data link to flares. The reverse is also visible in the threads: people describe staying off all medicines for over a year while breastfeeding and then flaring, or stopping a biologic during breastfeeding and resuming it only after weaning (r/UlcerativeColitis, r/UlcerativeColitis). Those are individual stories, not evidence, but they are the pattern the Kane and Yu data describe.

We are not telling you to start, stop or change anything. We are telling you that "I'll come off my medicine so I can breastfeed" is a decision the evidence suggests is often unnecessary, and one to make only with your IBD team.

Does weaning make UC better?

People do ask this, often after months of flaring postpartum while still nursing (r/UlcerativeColitis). In that thread, replies went every direction: no change after weaning, worse after weaning, and a sense of having more energy to manage the flare once feeding demands dropped. We found no study that measured UC activity before and after weaning. If you are flaring while breastfeeding, the evidence points to treating the flare, not to weaning as a treatment.

"Detected in breast milk" does not mean "absorbed by your baby"

This is where most of the fear lives, so it is worth getting the mechanism straight. Almost every UC medicine reaches breast milk to some degree. The question that matters is how much, and how much of that your baby actually absorbs.

What the biologic studies measured

The largest dataset comes from the PIANO registry in the US (Matro 2018). Researchers collected 72 breast milk samples from women on biologics and measured drug levels at intervals after each dose:

Other studies give the scale relative to blood. In five women on vedolizumab, milk levels never exceeded 480 ng/mL, roughly one hundredth of serum levels (Lahat 2018). In one Japanese mother with UC on ustekinumab, the ratio of total milk exposure to total serum exposure was 0.0008 (Saito 2022). That case report also found ustekinumab in the baby's blood, but the timing points to the pregnancy rather than the milk: the mother's last dose was at 29 weeks of gestation, the baby was born at 38 weeks, and the infant sample was taken 71 days after that last dose, about a week after birth and weeks before she restarted the drug at 7 weeks postpartum. The authors describe the drug as being eliminated rapidly from the baby's body.

Why the old "it's not in the milk" studies were wrong, and why it does not matter

One r/UlcerativeColitis commenter said a maternity hospital pharmacist had told her the biologic molecules "would be too large to pass into breast milk" (r/UlcerativeColitis). That idea has a real source. A 2009 study of three mothers on infliximab found the drug "undetectable" in their milk and in their babies' blood (Kane 2009).

Two years later, an Israeli group measured infliximab in the milk of three nursing mothers and found it rising to as much as 101 ng/mL within two to three days of an infusion, about 1/200th of the blood level (Ben-Horin 2011).

So "too large to pass into milk" is not accurate. Small amounts do pass. What the evidence actually supports is the next step: these are large proteins, and a baby's gut is expected to break most of them down rather than absorb them. LactMed, the US National Library of Medicine's lactation database, describes vedolizumab as "likely to be partially destroyed in the infant's gastrointestinal tract" with absorption "probably minimal", and says the same of ustekinumab (LactMed: vedolizumab; LactMed: ustekinumab). The UK product information for infliximab says systemic exposure in a breastfed infant "is expected to be low because infliximab is largely degraded in the gastrointestinal tract", while also noting that infliximab has been detected in infant serum after breast milk exposure (Remicade SmPC).

The outcome that matters: how the babies did

Drug levels are a proxy. What you want to know is whether breastfed babies of mothers on these drugs got sick more or developed differently. The PIANO registry answered that for 824 women with IBD, 620 of whom breastfed (Matro 2018):

• At 12 months, 39% of breastfed babies and 39% of non-breastfed babies had had any infection (P greater than 0.99).
• Developmental milestone scores were 87 versus 86.
• Infection rates and milestones did not differ between babies whose mothers took biologics, immunomodulators or both, and babies whose mothers took only mesalamine, steroids or nothing.

This is an observational registry, so it cannot rule out small effects or rare events. It is also the largest real-world answer available, and it found nothing.

A number that looks alarming and is not: the 20.9% relative infant dose

If you read the vedolizumab lactation study funded by its manufacturer, you will see a figure that can stop you in your tracks: an average "relative infant dose" of 20.9% (Sun 2021). The same abstract also says milk levels were about 0.4% to 2.2% of serum levels. Both are correct. They measure different things.

The relative infant dose in that paper was calculated as the total amount a baby would swallow across an eight-week dosing interval, adjusted for body weight, compared with the mother's weight-adjusted dose over the same eight weeks. Because a baby drinks a lot of milk relative to its body weight, and the drug sits in milk for weeks after each infusion, that cumulative figure comes out large even though the concentration in any single feed is low. What the calculation cannot tell you is how much of a swallowed antibody a baby absorbs, and for large proteins that is expected to be very little.

The study was funded by Takeda, which makes vedolizumab, and several authors were Takeda employees, as the paper discloses. It concluded that vedolizumab was "present in human breast milk at a low level." We mention the 20.9% because you may find it, and it deserves context rather than either alarm or dismissal.

Drug by drug: what is known while breastfeeding

This is a summary of what the sources say about each group of UC medicines. It is not a recommendation for you. Your own decision depends on how active your colitis is, what has worked before, and your baby's health, including whether they were premature.

The sections below explain the rows that come up most in the threads.

Mesalamine and sulfasalazine

These are the most common UC medicines in the r/UlcerativeColitis breastfeeding threads, and the most reassuring. Commenters describe breastfeeding for one, two or nearly three years on mesalamine, including at the higher end of the dose range and alongside rectal forms (r/UlcerativeColitis, r/UlcerativeColitis).

LactMed's summary: mesalamine is poorly excreted into breast milk, but "rather high levels" of its metabolite N-acetyl-5-ASA appear, and the effects of that metabolite on babies are unknown (LactMed: mesalamine). A few cases of diarrhoea have been reported in exposed infants, "although the rate is not high". Its advice is that mesalamine "is not a reason to discontinue breastfeeding", with careful observation of the baby for diarrhoea.

Sulfasalazine carries one extra consideration. Its sulfapyridine component reaches milk and infant blood and might cause haemolysis, "especially in newborn infants and in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency", and bloody diarrhoea has been reported in one infant (LactMed: sulfasalazine). LactMed still describes it as acceptable, while noting that mesalamine derivatives without a sulfonamide "are preferred". If your baby has G6PD deficiency, was born early or has jaundice, that is a specific question for the paediatrician.

Steroids

Prednisolone reaches milk in very small amounts and no adverse effects have been reported in breastfed infants with any corticosteroid (LactMed: prednisolone). You may have been told to wait four hours after a dose before feeding. Some people in the threads did exactly that, pumping and discarding for four hours after prednisone (r/UlcerativeColitis). LactMed says this wait is often recommended but "is not necessary because prednisolone milk levels are very low."

The steroid detail that rarely gets mentioned is supply. LactMed notes that "medium to large doses of corticosteroids given systemically" have been reported to cause a temporary reduction in milk production. If you start a steroid course during a postpartum flare and your supply dips, that may be why, and a lactation consultant can help you protect it.

Budesonide, whether oral or rectal, is only about 9% bioavailable when swallowed, and LactMed expects any that reaches milk to be similarly poorly absorbed by the baby (LactMed: budesonide). Expert opinion considers oral and rectal corticosteroids acceptable during breastfeeding.

Azathioprine and mercaptopurine

Thiopurines used to be the drug class mothers were most often told to avoid while nursing. The data have moved that advice. A Danish study measured the active metabolite, 6-mercaptopurine, in the milk and blood of eight women with IBD taking azathioprine (Christensen 2008). Milk levels were far lower than blood levels, peaked about an hour after the blood peak, and most of the drug in milk was excreted within the first four hours after a dose. The authors estimated the infant's intake at below 0.008 mg per kg of body weight per day.

An Austrian follow-up compared 15 babies breastfed by 11 mothers on azathioprine with 15 babies breastfed by 12 mothers not on immunosuppressants, at a median age of three to five years (Angelberger 2011). All children had age-appropriate development, infections were the usual childhood ones, and there was no difference in hospitalisation rates. It is a small study, and that is the honest size of the evidence. The PIANO registry adds that babies of mothers on immunomodulators did not have more infections or developmental delay (Matro 2018).

Whether to time feeds around doses is a question to ask your team. The Danish authors did not recommend it; they described breastfeeding on azathioprine as safe and something that "should be recommended".

Anti-TNFs, vedolizumab and ustekinumab

Covered above: low levels in milk, likely little absorbed, and no excess infections or developmental problems in the largest registry. One extra point from LactMed concerns supply rather than safety: anti-TNF drugs appear to reduce TNF levels in the milk of mothers with IBD early after delivery, and LactMed suggests this "might lead to decreased milk production, so extra lactation support might be necessary in women taking infliximab" (LactMed: infliximab). That is a hypothesis, not a measured effect, but if your supply is struggling it is a reason to ask for help early rather than assume you are doing something wrong.

Several drug summaries in LactMed also note that waiting at least two weeks after birth to restart a biologic that was paused in pregnancy may reduce transfer to the baby, while also noting that continuing it after a late-pregnancy dose did not prolong the baby's elimination. That is a timing question for your IBD team, not something to act on alone.

JAK inhibitors and S1P modulators: where the line is drawn

These are the drugs the consensus says not to breastfeed on, and the reason is the absence of data, not evidence of harm. LactMed's tofacitinib entry reports data from just three mothers, with low milk levels and no adverse effects in their exclusively breastfed babies, but says expert opinion considers breastfeeding "unadvisable" at this time, and notes the manufacturer recommends stopping breastfeeding during treatment and for a period after the last dose (LactMed: tofacitinib). For upadacitinib, LactMed says milk amounts are low but there is no information on clinical use during breastfeeding, and that the manufacturer recommends withholding breastfeeding for six days after the last dose (LactMed: upadacitinib).

Ozanimod shows how messy the sources can get. The consensus says mothers on S1P modulators should not breastfeed. LactMed notes that some guidelines recommend avoiding ozanimod because of a lack of data, that it has a slow clearance and long half-life, and that "the manufacturer's labeling does not recommend against the use of ozanimod in breastfeeding" (LactMed: ozanimod). So the label and the consensus point in different directions. The consensus is the more cautious and the more recent IBD-specific source.

If a JAK inhibitor or S1P modulator is the drug that controls your UC, this is a real dilemma, not a box to tick. People in the threads describe stopping breastfeeding to start one of these drugs (r/UlcerativeColitis), and one described switching to formula during a flare partly so they could try new medicines without worrying about their nursing baby (r/UlcerativeColitis). Your options are a conversation with your IBD team about whether a breastfeeding-compatible alternative is realistic for your disease, and if it is not, a decision about feeding that puts your health first. The consensus guiding principle, stated in its abstract, is that "maternal health best supports infant health" (Mahadevan 2025).

Methotrexate: genuinely contested

Methotrexate is used less often in UC than in Crohn's, but it comes up. The consensus recommends stopping it before conception. In the lactation statements we read, it is not mentioned at all. LactMed reports that low milk levels are produced and that recent guidelines in other specialties describe low weekly doses as an acceptable alternative during breastfeeding, "although some older expert opinion warns against this use" (LactMed: methotrexate). In the 2025 survey, 68% of gastroenterologists advised against methotrexate while breastfeeding (Casanova 2025). If methotrexate is on the table for you, ask specifically, and expect the answer to vary.

Live vaccines: the question your doctors may answer differently

If there is one topic where people with UC get contradictory advice, it is this. A Crohn's thread captures it: a mother told months earlier she could breastfeed on ustekinumab was then told, a few weeks before delivery, that her baby could not have live vaccines while she breastfed (r/CrohnsDisease). Other commenters in the same thread had been told different things by different doctors: wait six months, follow the normal schedule, skip rotavirus.

Part of the confusion is that two separate exposures get mixed up.

Exposure in the womb. Antibody drugs such as infliximab, adalimumab and ustekinumab cross the placenta in late pregnancy, and babies can carry measurable levels for months. That is the exposure behind most live-vaccine caution.

Exposure through breast milk. As covered above, much smaller amounts, largely broken down in the baby's gut.

Here is what the sources say about each:

Sources: Mahadevan 2025 and the Remicade SmPC.

So the UK label for infliximab and the 2025 consensus give opposite answers on breast milk exposure. A 2022 commentary by a group of UK clinicians explained how this happened (Selinger 2022). The UK and European medicines regulators issued guidance that infants exposed to infliximab through breast milk should avoid live vaccines. The authors wrote that "there is no credible evidence" that the small amounts in milk lead to clinically significant infant blood levels, that in the few cases where infant levels were reported most babies had in-womb exposure, and that the guidance risked mothers choosing not to breastfeed. They called for "a nuanced approach".

Clinicians are split too. In the 2025 survey, half of gastroenterologists advised avoiding live vaccines for the first 12 months in babies exposed to anti-TNF in the womb, and between 8% and 14% advised against live vaccines even beyond 12 months for babies exposed only through breastfeeding, depending on the biologic (Casanova 2025).

Will breastfeeding protect my baby from getting ulcerative colitis?

The honest answer is that the evidence now conflicts, and the stronger recent study found no effect.

This came up in a 48-comment r/UlcerativeColitis thread where a parent hoped breastfeeding would help their children avoid the disease their partner had (r/UlcerativeColitis). The replies were a long list of people who were breastfed for years and still developed UC, alongside others who had been formula-fed and had not, and a few who pointed out the confounding in the research.

The case for protection comes from a 2017 meta-analysis of 35 studies including 7,353 people with UC (Xu 2017). Ever being breastfed was associated with lower UC risk (odds ratio 0.78), and being breastfed for at least 12 months more so (odds ratio 0.21 compared with 3 or 6 months). The authors concluded that breastfeeding protects against UC. But most of the studies were case-control designs, which ask adults with and without IBD, or their parents, to recall infant feeding decades later.

In 2024, a study using prospectively collected data from three population-based birth cohorts in Denmark, Norway and Sweden, covering more than 148,000 children followed for a median of 16 to 22 years, found something different (Agrawal 2024). After adjusting for parental IBD, maternal education, smoking in pregnancy, mode of delivery, prematurity and more, neither exclusive nor any breastfeeding duration was associated with IBD risk, including UC specifically. Children exclusively breastfed for six months or more had a hazard ratio of 1.24 (95% CI 0.94 to 1.62) compared with four to five months. One limitation is worth knowing: this study compared different breastfeeding durations against each other, so it says less about breastfeeding versus none at all.

These two studies cannot both be right about duration. The prospective design of the 2024 study makes it harder to dismiss, but it was not designed to settle the never-breastfed question. What both sides agree on is that family history matters: the consensus says children with a first-degree relative with IBD have a higher risk of IBD, and that the risk may be higher when the parent has Crohn's than when the parent has UC (Mahadevan 2025).

So breastfeed for the reasons you want to, but do not carry guilt if you cannot or choose not to. The evidence does not support the idea that your feeding choice decides whether your child gets UC.

Colonoscopy, sigmoidoscopy and bowel prep while breastfeeding

Postpartum flares often mean a scope, and the threads are full of conflicting instructions about what that means for feeding: pump and discard for 6 hours, for 24 hours, until the next day, or not at all (r/UlcerativeColitis). One person in that thread pumped and discarded until the following day after a flexible sigmoidoscopy and lost her supply, then rebuilt it with frequent nursing.

The best guidance we found comes from the Association of Anaesthetists' 2020 guideline on anaesthesia and sedation in breastfeeding women (Mitchell 2020). It says that inconsistent advice can lead to interruptions of 24 hours or longer and to "pumping and dumping", which "may contribute to early cessation of breastfeeding", and advises that breastfeeding "is acceptable to continue after anaesthesia and should be supported as soon as the woman is alert and able to feed, without the need to discard breast milk." It provides drug-by-drug data so that professionals can discuss specifics with you.

For the prep itself, polyethylene glycol (the base of most bowel preps) is very poorly absorbed from the gut, so LactMed says it does not enter breast milk and needs no special precautions (LactMed: polyethylene glycol). Other prep formulations exist, so check the one you are given.

Flares, milk supply and your body

A flare while breastfeeding is not only a medicine question. People describe their supply dropping when they could barely digest enough food during a flare (r/UlcerativeColitis), and others describe the combined drain of broken sleep, a healing caesarean wound and a flare (r/UlcerativeColitis).

We found no study that measures milk supply in breastfeeding mothers with active UC, so we cannot give you a figure. What the sources do support:

• Higher-dose steroids have been reported to temporarily reduce milk production (LactMed: prednisolone).
• Anti-TNF drugs may, in theory, affect production via lower TNF in milk, and LactMed suggests extra lactation support (LactMed: infliximab).
• Blood loss and iron deficiency are common in active UC and add to postpartum fatigue. Our article on UC fatigue and low iron covers how ferritin is read when inflammation is present, which matters after a birth with blood loss too.

What to eat during a flare is its own subject, covered in what to eat during a UC flare. The short version for nursing mothers: eating less to feel better during a flare carries its own nutritional cost, and that cost is higher when you are also producing milk. A dietitian with IBD experience is worth asking for.

Is combination feeding a reasonable middle ground?

It is a legitimate option, and the threads show many people using it: topping up with formula to protect sleep, switching to bottles when a flare made nursing impossible, or combining feeds while starting a new drug (r/UlcerativeColitis, r/UlcerativeColitis). We found no study comparing exclusive breastfeeding with combination feeding in mothers with UC, so there is no evidence-based answer to "which is better for my colitis". There is also no evidence that combination feeding is unsafe for either of you. If someone else can take a night feed with expressed milk or formula, the sleep may matter as much to your recovery as anything else.

Who to ask, and what to bring

The queue of people who might answer your breastfeeding question is long: your gastroenterologist, IBD nurse, obstetrician or midwife, maternal-fetal medicine specialist, paediatrician, health visitor, lactation consultant and pharmacist. Each knows part of the picture. Reddit commenters describe getting a green light from the pediatrician, the GI and a nursing consultant before trusting it (r/UlcerativeColitis), and others describe a hospital pharmacist giving a reassuring answer for the wrong reason (r/UlcerativeColitis).

A sensible division of labour:

• Your IBD team decides your treatment. Whether to continue, restart, switch or step up is their call with you, and the 2025 consensus is the document to anchor that conversation.
• The paediatrician owns your baby's side: vaccines, monitoring for diarrhoea or jaundice, prematurity, G6PD.
• A lactation consultant handles supply, latch and pumping, including around infusions, scopes and steroid courses.
• A pharmacist can check any single new drug, including antibiotics for mastitis, pain relief after a caesarean and anything prescribed in a hurry.
• LactMed is free and public. Searching a drug name on PubMed or the NIH Bookshelf brings up its entry, with the evidence and its date.

If you are still preparing for a pregnancy rather than in the postpartum weeks, our list of questions to ask a gastroenterologist about colitis includes the lactation question to raise early, and pregnancy with a j pouch covers the post-surgery version of these decisions.

A worked example: one week, four decisions

Here is how these pieces fit together for one composite person. This is an illustration, not a case history or advice.

Maya has left-sided UC and was on vedolizumab and mesalamine through her pregnancy. Her baby is five weeks old and exclusively breastfed. She starts having more frequent stools with some blood.

1. Is this a flare or postpartum bowel chaos? She has had haemorrhoids since delivery, which bleed. She checks her stool pattern against her pre-pregnancy baseline rather than against last week, and the frequency is clearly up. She contacts her IBD nurse, who arranges a calprotectin test. (Our guide to whether UC is flaring explains why calprotectin and symptoms can disagree.)
2. The team suggests a short steroid course. She asks whether to wait four hours before feeding. Her team points out that the lactation database describes that wait as unnecessary for prednisolone, and flags that her supply may dip, so she books a lactation consultant.
3. A sigmoidoscopy is planned. She pumps the day before, asks the sedation team to confirm she can feed once she is alert, and gets that written on her discharge sheet.
4. The 8-week vaccines are coming. She realises nobody has discussed rotavirus. She sends the paediatrician a short note listing vedolizumab in pregnancy (last dose date) and vedolizumab now, and asks the IBD team and the paediatrician to agree a plan.

At no point did breastfeeding itself decide anything. Every decision was about treating the colitis and protecting the feeding she wanted to continue.

What to track in the postpartum months

Postpartum UC is hard to read because so much changes at once: hormones, sleep, diet, haemorrhoids, iron, a recovering perineum or caesarean wound. A few weeks of plain notes make every one of the conversations above faster. Worth recording:

• Daily stool frequency, urgency and blood, against your pre-pregnancy normal rather than against last week. Our IBD symptom diary guide explains how to write that baseline down.
• Every medicine with dates: when you restarted or changed a biologic after delivery, steroid courses, antibiotics, pain relief. These are the dates the paediatrician will ask about for vaccines.
• Feeds and supply, at least roughly: if supply drops, you want to know whether it followed a steroid course, a flare or a scope.
• Your baby's stools, only if your paediatrician asks you to watch for diarrhoea on mesalamine or sulfasalazine.

Clairop lets you log bowel movements and symptoms in seconds and produces a one-page summary for your GI appointment that includes your medication adherence. It does not tell you whether a medicine is compatible with breastfeeding or whether you are flaring; that stays with your team.

When to see a doctor promptly

Contact your IBD team or seek urgent care promptly if you have:

• More blood than usual, blood clots, or bloody stools that keep increasing in number.
• Fever, a racing heart or feeling faint, especially with bloody diarrhoea.
• Signs of dehydration: dizziness, very little urine, a dry mouth, particularly if you are also breastfeeding through diarrhoea.
• Severe or constant abdominal pain or a swollen, tender abdomen.
• Leg pain or swelling, chest pain or sudden breathlessness. The consensus warns that women with IBD have a higher risk of blood clots in the postpartum period (Mahadevan 2025). These need same-day assessment.
• Breast redness, heat and fever, which may be mastitis and may need a drug decision that takes your IBD medicines into account.

For your baby, contact the paediatrician promptly about diarrhoea, blood in the nappy, poor feeding, unusual sleepiness, yellow skin or eyes, or any fever in a young infant. Mention which IBD medicines you took in pregnancy and take now.

Our guide to when to go to the hospital for a UC flare covers the admission thresholds in more detail.

Myths about breastfeeding with UC

"Biologic molecules are too big to get into breast milk." They do get in, at low levels: infliximab was found in the milk of 19 of 29 women in the largest study (Matro 2018). The reassurance comes from the low amount and the baby's gut breaking it down, plus the outcome data, not from the drug being absent.

"If a drug is fine in pregnancy, it is fine for breastfeeding." Mostly true for UC drugs, which is why the consensus lists are so similar, but not a rule. Each drug has its own lactation data, and some advice, such as live-vaccine timing, differs between the two exposures.

"Breastfeeding makes UC flare." The study that first suggested it found the link disappeared once women stopping their medication was accounted for, and found no association at all in UC (Kane 2005).

"You must pump and dump after sedation, infusions or steroid doses." The UK anaesthetists' guideline says feeding can resume once you are alert, without discarding milk, after most anaesthetic drugs (Mitchell 2020). LactMed calls the four-hour steroid wait unnecessary for prednisolone. We found no source recommending discarding milk after a biologic infusion.

"Breastfeeding will stop my child getting UC." The largest prospective study found breastfeeding duration made no difference (Agrawal 2024). Family history matters more, and nothing you do with feeding cancels it.

"Every gastroenterologist knows the rules." In a 2025 survey, 13% believed all IBD drugs were safe while breastfeeding, and many would not have advised against the JAK inhibitors and S1P modulators the consensus says to avoid (Casanova 2025). Asking which source a recommendation comes from is reasonable, not rude.

The honest bottom line

You can breastfeed with ulcerative colitis on almost every treatment used for it today. The newest global consensus recommends it, the largest registry found no difference in infections or development for babies whose mothers were on biologics, and breastfeeding has not been shown to cause flares. The two drug classes to stop and ask about are JAK inhibitors and S1P modulators, and methotrexate is a genuine grey zone.

The risks that show up in the data are elsewhere: stopping treatment to breastfeed, getting inconsistent advice about live vaccines, and losing supply to unnecessary pump-and-dump instructions. Those are fixable with the right questions asked early. And if, at any point, the healthiest choice for you is formula, partly or fully, that is a choice the consensus itself supports: its guiding principle is that your health is what best supports your baby's.